Abbott Laboratories' End-Markets Remain Healthy Despite Mixed Q1 Performance, RBC Says

MT Newswires Live04-17

Abbott Laboratories' (ABT) end-markets remain healthy despite a lower 2026 organic revenue guidance amid fiscal Q1 challenges and mixed performance, RBC Capital Markets said in a Thursday research note.

The company faced Q1 headwinds, including a weaker respiratory season, underperformance in the continuous glucose monitoring segment, challenging US structural heart business trends, and roadblocks in the nutrition sector, analysts wrote.

The brokerage said it expects 2026 EPS of $5.48 on revenue of $50.54 billion.

The company has visibility to accelerate growth in H2, driven by emerging signs of nutrition business recovery, electrophysiology unit growth, improvements in the core lab diagnostics unit, robust performance in established pharmaceuticals, and the integration of Exact Sciences in the cancer diagnostics business, according to the note.

The brokerage reiterated its outperform rating on the stock and adjusted its price target to $130 from $135.

Price: 96.67, Change: +1.20, Percent Change: +1.26

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment